Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul 23;36(8):1399-1407.
doi: 10.1093/ndt/gfaa116.

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

Mark Sampson  1 , Nuno Faria  2   3 , Jonathan J Powell  2   3 ; PEACH study investigators
Affiliations
Clinical Trial

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

Mark Sampson et al. Nephrol Dial Transplant. .

Abstract

Background: Hyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders.

Methods: In this double-blind, parallel-group, placebo-controlled, dose-ranging study (ClinicalTrials.gov identifier NCT02151643), the efficacy and safety of 28 days of oral PT20 treatment were evaluated in patients with dialysis-dependent CKD. Participants were randomly assigned in an 8:8:8:13:13 ratio to receive PT20 (400, 800, 1600 or 3200 mg) or placebo three times daily.

Results: Among 153 participants, 129 completed treatment [7 discontinued because of adverse events (AEs), 2 because of hyperphosphataemia and 15 for other reasons]. PT20 treatment for 28 days resulted in a statistically significant and dose-dependent reduction in serum phosphate concentration. There were no statistically significant effects of PT20 treatment on changes in haemoglobin or ferritin concentrations or transferrin saturation between Days 1 and 29. The incidence of treatment-emergent AEs was broadly similar across the PT20 and placebo groups (42-59% versus 44%). The most common PT20 treatment-related AEs were gastrointestinal, primarily diarrhoea (13-18%) and discoloured faeces (3-23%). No serious AEs were considered to be related to study treatment. There were no clinically significant changes in laboratory results reflecting acid/base status or increases in ferritin that could indicate the absorption of components of PT20.

Conclusions: In this first study investigating the efficacy and safety of PT20 in patients with hyperphosphataemia and dialysis-dependent CKD, PT20 significantly lowered serum phosphate concentrations and was generally well tolerated.

Keywords: PT20; chronic kidney disease; ferric oxide; hyperphosphataemia; phosphate binder.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1
FIGURE 1
Patient disposition.
FIGURE 2
FIGURE 2
Mean change in serum phosphate concentration from Day 1 to 29 in patients receiving placebo or PT20 400, 800, 1600 or 3200 mg, each given TID (ITT population).
FIGURE 3
FIGURE 3
Mean change in serum phosphate concentration from Day 1 to 29, by dose group (ITT population). The blue data points represent baseline values for the placebo group and each of the treatment groups in ascending order. The red data points show the change from baseline assessed at Day 29 for the placebo group and each of the treatment groups in ascending order. A significant dose-dependent change in serum phosphate concentration over time is shown by the log(dose)/effect slope (P < 0.001).
See this image and copyright information in PMC

References

    1. Block GA, Hulbert-Shearon TE, Levin NW. et al.. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617 - PubMed
    1. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Semin Dial 2007; 20: 286–294 - PubMed
    1. Port FK, Pisoni RL, Bommer J. et al.. Improving outcomes for dialysis patients in the International Dialysis Outcomes and Practice Patterns study. Clin J Am Soc Nephrol 2006; 1: 246–255 - PubMed
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–S201 - PubMed
    1. Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1–59 - PMC - PubMed

Publication types

Associated data